False-Positive PET-CT Results: Which Conditions Mimic Cancer?
In this article
False-Positive PET-CT Results: When Does Imaging “Mimic Cancer”?
Positron Emission Tomography–Computed Tomography (PET-CT) is one of modern oncology's most powerful tools for cancer staging and monitoring treatment response. However, 18F-FDG is taken up not only by tumor cells but also by many noncancerous processes such as infection and inflammation. These can produce “false-positive” findings in the report—areas that resemble cancer on imaging.
1. The FDG Mechanism: What Do We See and What Do We Miss?
The most commonly used PET-CT radiotracer is 18F-FDG (fluorodeoxyglucose). FDG resembles glucose and enters cells through GLUT transporters . Cancer cells need substantial energy for rapid proliferation, so they generally consume more glucose and FDG, appearing brighter on PET.
The same mechanism, however, operates in active infection, inflammatory disease, healing tissue, muscle and brown adipose tissue . FDG PET therefore reveals high metabolic activity; additional information is essential to determine whether it represents cancer, infection or a physiological process .
FDG-Positive Does Not Mean Cancer
High FDG uptake (a high SUV value) is an important diagnostic clue but does not diagnose cancer by itself. PET-CT must be interpreted alongside clinical history, laboratory tests, CT/MRI and biopsy when needed.
2. Infection and Inflammation: PET-CT's Greatest Mimics
Activated leukocytes, macrophages and T lymphocytesconsume substantial glucose while fighting infection. Infectious and inflammatory diseases therefore frequently cause false-positive foci on PET-CT. This may complicate clinical decisions, particularly when assessing lungs and lymph nodes.
-
Lung infections: Pneumonia, organizing pneumonia and lung abscesses may mimic lung cancer or metastases with high SUV values.
-
Tuberculosis and sarcoidosis: Intense, often symmetrical FDG uptake in mediastinal and hilar lymph nodes can resemble lymphoma or lung cancer spread. This is especially important in countries such as Turkey, where tuberculosis is common.
-
Chronic infection: Osteomyelitis, prosthetic infections, chronic sinusitis and liver/splenic abscesses may produce intense foci confused with malignancy.
Uptake After Surgery and Radiotherapy
After major surgery or radiotherapy, the affected area may show healing-related inflammation lasting months. Increased FDG in these areas may resemble recurrence/metastasis, particularly early on. Therefore:
- After surgery, generally at least 6–8 weeks are allowed to elapse.
- “Geographic” uptake confined to a radiation field often suggests radiation pneumonitis or fibrosis.
Timing provides valuable context for the nuclear medicine specialist.
3. Physiological Uptake: The Body's Natural Bright Spots
Even without cancer or disease, some tissues consistently show marked FDG uptake because of high energy consumption. Recognizing these patterns prevents unnecessary anxiety and inappropriate further investigations.
-
Brain: Neural tissue is continuously active and physiologically takes up FDG intensely and homogeneously. This high activity is normal, and assessment generally focuses on other organs.
-
Heart muscle: FDG uptake may vary, particularly after meals. In dedicated cardiac scans, diet and preparation protocols are adjusted accordingly.
-
Brown adipose tissue: Brown fat in the neck, supraclavicular and paravertebral regions, particularly activated by cold, may appear as symmetrical bright areas mimicking lymph node metastases.
-
Muscle activity: Strenuous exercise, tension, speaking or chewing before scanning may increase FDG uptake in the relevant muscles. Patients are therefore advised before scanning to rest and minimize muscle activity .
-
Intestines: Heterogeneous uptake in the small bowel and colon due to peristalsis and mucosal activity may be physiological. Focal uptake requires closer evaluation.
4. Benign Tumors: Bright Lesions That Are Not Cancer
Some benign tumors and hyperplastic lesions show intense uptake because of high cellularity and metabolic activity. Particularly in the thyroid, uterus, colon and salivary glands, this may produce false-positive suspicion of cancer .
Thyroid and Salivary Glands
Thyroid adenomas, Graves disease and thyroiditis, as well as Warthin tumors in salivary glands, may show intense FDG uptake. Warthin tumors, particularly in the parotid, can have high SUVs despite being benign.
Uterus and Fibroids
Uterine fibroids, particularly large and highly cellular ones, may show marked PET-CT uptake. Menstrual cycle-related endometrial activity must also be considered.
Bowel Polyps
Villous adenomas and some hyperplastic colon polyps may show increased FDG uptake. These findings should be confirmed by colonoscopy; every PET-positive segment should not immediately be labeled “cancer.”
Nerve Sheath Tumors and Others
Benign lesions such as schwannomas, neurofibromas and some hemangiomas can also show intense uptake. PET-CT must therefore always be interpreted with CT/MRI morphology and clinical information .
5. SUV and Technical Factors: Why Numbers Do Not Tell the Whole Story
Often reported on PET-CT, SUVmax is a numerical measure of standardized FDG uptake. SUV depends not only on tumor biology but also on fasting duration, blood glucose, injection-to-scan interval, scanner differences and reconstruction algorithms , among other technical factors.
For example, tuberculosis foci may have SUVmax 15 or higher, while some low-grade lung cancers (carcinoid tumors) remain at SUVmax 2–3. Experienced nuclear medicine specialists therefore assess SUV alongside lesion shape, location and clinical context , rather than alone.
The European Association of Nuclear Medicine (EANM) and other guidelines recommend for oncological FDG PET-CT:
- At least 4–6 hours of fasting,
- Controlled blood glucose,
- A standardized injection-to-scan interval,
- The same scanner and similar protocols for repeat examinations
Meeting these conditions allows reliable monitoring of changes over time.
6. The Nuclear Medicine Specialist: The Physician Reading the Map
Raw PET-CT output is a metabolic intensity mapof bright and dark areas. To translate it into clinical reality, the nuclear medicine specialist assesses it with radiology, medical oncology, radiation oncology and, when needed, surgery.
1. Pattern Recognition
Uptake shape, symmetry and distribution are almost as valuable as diagnosis itself. For example: linear esophageal uptake often suggests reflux/esophagitis, while focal nodular uptake may suggest a tumor.
2. CT / MRI Correlation
PET shows only “increased activity.” By examining CT of the same area, the specialist distinguishes a calcified granuloma, fluid-filled cyst, fibrosis or an actual mass. This correlation is fundamental to excluding false positives.
3. Integrating Clinical History
An infection within recent weeks, a new biopsy, dental treatment, recent vaccination or radiotherapy may explain why many “suspicious” foci are noncancerous. Sharing detailed clinical information is therefore essential.
4. Contributing to Biopsy and Follow-Up Decisions
For some foci, immediate biopsy is appropriate; for others, short-interval PET/CT or CT follow-up may be better. The nuclear medicine specialist answers, “biopsy now or monitor first?” together with the oncology team.
The signature on your PET-CT report therefore represents a physician who interprets more than images: the entire clinical context is considered. An experienced reading of the same scan can exclude many false-positive findings.
PET-CT Positivity ≠ A Definite Cancer Diagnosis
On a PET-CT report, “increased FDG uptake”, “high SUV” or “hypermetabolic focus” can cause intense anxiety. Yet these findings also occur with infection, inflammation, benign tumors and entirely physiological processes. PET-CT is therefore not the sole judgeof diagnosis but a powerful contributor: Decisions must combine clinical findings, laboratory tests, other imaging and biopsy when needed.
- Long NM, Smith CS. (2011): Causes and Imaging Patterns of False-Positive Findings on 18F-FDG PET/CT in Oncology. RadioGraphics;31(7):1915–1938.
- Chang JM et al. (2006): False Positive and False Negative FDG-PET Scans in Various Thoracic Diseases. Korean J Radiol;7(1):57–69.
- Metser U, Even-Sapir E. (2010): Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and pitfalls. AJR Am J Roentgenol;194(2):W201–W209.
- Boellaard R et al. (2015): FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging;42:328–354.
- Treglia G. (2019): Diagnostic performance of 18F-FDG PET/CT in infectious and inflammatory diseases. BioMed Research International.
- Calabria FF et al. (2024): FDG PET/CT in inflammatory and infectious diseases including sarcoidosis. Diagnostics.
- Budak ES et al. (2018): The contribution of 18F-FDG PET/CT to lung cancer diagnosis and staging. Molecular Imaging and Radionuclide Therapy.
- Radiopaedia.org: “False positive FDG PET” (access year: 2024).
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.